Angioedema News

“Cubist brings a wealth of clinical resources and commercial expertise in the development of a hospital-based therapy, which will serve to maximize the potential of DX-88 in the prevention of blood loss during surgery”

CAMBRIDGE, Mass. & LEXINGTON, Mass.-- --Dyax Corp. and Cubist Pharmaceuticals, Inc. via BioSpace

Comment?

“Patients with hereditary angioedema live with the constant threat of severe and potentially life-threatening angioedema attacks”

Lev Presents Results of Phase III Study Supporting Safety and Efficacy of Cinryze as Prophylactic Therapy for HAE PHILADELPHIA & NEW YORK-- --Mar 18, 2008 - Lev Pharmaceuticals, Inc. via Med Ad News

Comment?

“It's a very promising drug that we've had excellent results with”

While it awaits results from a confirmatory trial with hereditary angioedema drug DX-88, Cambridge, Mass.-based Dyax Corp. via BioWorld

Comment?

German biotech firm Jerini AG said on Friday that U.S. regulators at the Food and Drug Administration have granted priority review of its Icatibant drug for the treatment of skin-swelling disease hereditary ... via Reuters UK

Comment?

“It feels like the same issue right now”

Shares in Pharming Group NV sank by more than 65 percent on news that the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a negative opinion on a marketing authorization ... via BioWorld

Comment?

“The rarity of the diagnosis means that even the most specific of tests may be wrong”

Although there is currently no treatment approved by the Federal Drug Administration for acute attacks of hereditary angioedema - ' a genetic disease causing swelling of extremities, face and internal organs ... via Newswise

Comment?

Drug developer Dyax Corp. said Wednesday its third-quarter loss widened on higher costs for its DX-88 hereditary angioedema treatment candidate and lower revenue. via Canadian Business Magazine

Comment?